| Name | Title | Contact Details |
|---|---|---|
Madison Quinn |
Manager, Clinical Supply Chain | Profile |
Vishwas Setia |
Chief Financial Officer | Profile |
Chris Kroeger |
Chief Executive Officer | Profile |
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.
RUCDR Infinite Biologics Becomes Infinity BiologiX IBX will continue to advance RUCDR`s founding mission to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. IBX will continue to collaborate with – and provide services to – researchers in both the public and private sectors globally, including innovative and market-disrupting sample collection and processing, storage and analytical services, and scientific and technical support in both the research and clinical arenas.
SciMed Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.
miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies.